FDA Issues CRL to Elevar Therapeutics

The U.S. Food and Drug Administration (FDA) has issued a complete response letter to Elevar Therapeutics regarding its combination treatment for unresectable or metastatic hepatocellular carcinoma. The rejection stems from manufacturing deficiencies discovered during a facility inspection rather than concerns over the clinical safety or efficacy of the rivoceranib and camrelizumab pairing. This regulatory setback is significant for the oncology sector as the therapy had previously demonstrated a median overall survival of 23.8 months in Phase III trials.

The FDA's decision to issue a complete response letter (CRL) to Elevar Therapeutics centers on the company's proposed first-line treatment for liver cancer, which combines rivoceranib and camrelizumab. According to the report, the agency's primary concerns are rooted in manufacturing deficiencies identified during a recent facility inspection. Notably, the FDA did not cite issues with clinical efficacy or safety, which remains a strong point for the therapy; Phase III trial results indicated a median overall survival of 23.8 months for patients with unresectable or metastatic hepatocellular carcinoma. This development follows a recent FDA decision to pause the release of new CRLs pending a response to a citizen's petition.

This regulatory action occurs alongside a broader industry trend where direct-to-patient (DTP) pharmaceutical platforms are expanding rapidly, often outstripping the safety infrastructure required to support them. A new analysis highlights that prescriptions filled through these platforms frequently fail to integrate with a patient’s electronic health record, creating significant blind spots for physicians managing drug interactions and care coordination. This lack of coordination is particularly risky in fast-growing, stigma-sensitive categories such as metabolic health and mental health, where industry watchers urge platforms to prioritize primary care record integration as a product decision rather than waiting for regulation.

In other sector developments, Insilico Medicine has expanded its strategic partnership with China Medical System Holdings (CMS) through a new AI-powered drug discovery collaboration valued at up to $177 million. This deal focuses on a central nervous system indication and utilizes Insilico’s PandaOmics platform to identify novel mechanisms. The agreement, which includes milestone payments and royalties, follows a series of high-profile partnerships for Insilico in 2026, including collaborations with major players like Eli Lilly and SK Biopharmaceuticals, signaling continued momentum for AI-driven drug development in the global pharmaceutical market.